A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Apr 2018 Planned number of patients changed from 64 to 58.
- 11 Apr 2018 Planned End Date changed from 30 Dec 2020 to 30 Jun 2020.